RxDoctor Payments Data

Ashley Lundin, MD

Ophthalmology · Bemidji, MNNPI 1457649048

Payments from drug & device makers

$612in general payments, 2019–2025

Across 16 payments — averaging $38.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • The Cameron-ehlen Group, Inc.$280
  • Sight Sciences, Inc.$134
  • Glaukos Corporation$62
  • AbbVie$56
  • Alcon$39
  • Rxsight Inc$25
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
The Cameron-ehlen Group, Inc.5$280
Sight Sciences, Inc.3$134
Glaukos Corporation1$62
AbbVie3$56
Alcon2$39
Rxsight Inc1$25
Mallinckrodt Hospital Products Inc.1$16

How this compares

$612 in reported general payments places this provider in the 60th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$422,999
Medicare patients
844
Services billed
3,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$28,102
CombiganBrimonidine Tartrate/Timolol39$12,352
Latanoprost391$6,632
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$6,569
Prednisolone Acetate87$4,514
Cyclosporine11$2,541
Timolol Maleate179$2,490
Brimonidine Tartrate92$1,971
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat79$1,356
Fluorometholone21$1,268
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha66$848
Travoprost18$659
MoxifloxacinMoxifloxacin Hcl31$519
Dorzolamide Hcl30$516
Acyclovir23$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$56$40,45476 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →